Syngene International is a leading integrated contract research, development, and manufacturing organization (CRDMO). The company was honored with three awards at the 2024 Pharmaceutical Technology Excellence Awards, recognizing its achievements in Innovation, Business Expansion, and Environmental efforts.
The Pharmaceutical Technology Excellence Awards highlight key innovations and achievements in the pharmaceutical industry, powered by GlobalData’s business intelligence. These awards acknowledge those who are making a significant impact on the industry.
Go deeper with GlobalData
Syngene was recognized in the Innovation category for its advancements in drug discovery and development, while its growth and enhanced operations earned the Business Expansion award. The company’s focus on sustainable practices led to its recognition in the Environmental category.
Pioneering scientific advancements in drug discovery
Syngene’s Innovation award reflects its continuous drive to develop cutting-edge solutions in drug discovery. Key advancements include its AI-driven platforms like Syn.AI™, SynVent, SARchitect™, and SynSight™, which have transformed the drug discovery process. These platforms use artificial intelligence to improve target identification and molecule design, reducing late-stage failures and speeding up discovery timelines. For example, SynAI™ helps identify and prioritize disease targets, while SARchitect™ integrates data to guide R&D decisions. SynSight™ allows Syngene clients to share anonymized data for predictive modeling, leading to more reliable results.
Syngene also introduced SynWeave™, a protein production platform that reduces development timelines by up to 10 weeks and supports a wide range of biologics, including monoclonal antibodies, biosimilars, and other recombinant proteins.
Strategic growth through CRDMO expansion
The Business Expansion award highlights Syngene’s efforts to expand its capabilities and client base. A key milestone was the $55 million capital investment in the acquisition of a biologics manufacturing facility from Stelis Biopharma, which boosted Syngene’s biologics manufacturing capacity by more than 400%. This acquisition, which includes a state-of-the-art fill-finish unit, enhances Syngene’s ability to produce biologics more efficiently and at larger scales.
Syngene also expanded its facilities in Genome Valley, Hyderabad, with a planned investment of over $90 million. This new lab space will create up to 1,000 jobs, strengthening the company’s presence in the region and supporting long-term growth. The company’s expansion is supported by a robust supply chain. Syngene has built a resilient, ethical supply ecosystem by developing strong relationships with over 2,500 suppliers across 30 countries, ensuring the reliable delivery of materials and services to clients.
Commitment to sustainable practices
Syngene’s recognition in the Environmental category underscores its commitment to sustainability. It was awarded a Silver Medal in the EcoVadis sustainability rating, ranking among the top 15% of companies globally for its environmental, social, and governance (ESG) practices.
The company has set a target to reduce its greenhouse gas (GHG) emissions by 50% by 2033, in line with global climate goals. In 2023-24, Syngene reduced Scope 1 and 2 GHG emissions by 21% and Scope 3 emissions by 45%.
Syngene has also made significant progress in energy management, increasing its renewable energy use by 23% year-on-year and moving closer to its goal of sourcing 96% of its energy from renewable sources by 2028. The company has also reduced freshwater consumption by 42% and achieved zero waste to landfill, recycling 96% of its waste.
Syngene is dedicated to improving biodiversity as well. The company planted 2,400 saplings across its Bengaluru, Mangalore, and Hyderabad sites during a World Environment Day initiative and established two Miyawaki MicroForest sites in Mangalore.
Conclusion
Through consistent investment in R&D, digital transformation, and sustainable practices, Syngene is advancing healthcare solutions and setting new standards for innovation and environmental responsibility in the pharmaceutical sector.
“At Syngene, our commitment to scientific innovation, business growth, and sustainability lies at the heart of everything we do. By collaborating with our clients across the entire drug development and manufacturing continuum, we deliver outcomes that transform healthcare. Our focus on sustainability drives us to continuously refine processes, reduce environmental impact, and enhance efficiency, ensuring that we not only meet the evolving demands of the healthcare industry but also accelerate the delivery of life-changing therapies that improve patient outcomes globally.”
– Jonathan Hunt, MD & CEO, Syngene International
Company Profile
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s 5,656 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 million square feet of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit https://www.syngeneintl.com/
Links
Website: https://www.syngeneintl.com/
